EUVIMEDEUVIMED entdecken
Crossref

Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia

Angela Huynh, Donald M Arnold, Nikola Ivetic, Rumi Clare, Milena Hadzi-Tosev, Yang Liu, James W Smith, Anna-Lise Bissola, Mercy Daka, John G Kelton, Ishac Nazy

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.06.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Angela Huynh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Vaccines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, Public Health Agency of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare complication of adenoviral vector-based vaccines against SARS-CoV-2. This syndrome is caused by antibodies against platelet factor 4 (PF4; CXCL4) that lead to platelet activation and is characterized by thrombocytopenia and thrombosis in unusual locations, including cerebral venous sinus thrombosis (CVST). VITT can be classified based on anti-PF4 antibodies properties in vitro: those that require PF4 to activate platelets (PF4-dependent) and those that can activate platelets without additional PF4 (PF4-independent) in the serotonin release assay. OBJECTIVES: We aim to characterize the relationship of VITT platelet-activating profiles with CVST. METHODS: We conducted a retrospective cohort study involving patients with confirmed VITT who were tested between March and June 2021. Data were collected with an anonymized form and cases were identified as VITT with high clinical suspicion according to platelet activation assays. Anti-PF4 antibody binding regions on PF4 were further characterized with alanine scanning mutagenesis. RESULTS: Of the patients with confirmed VITT (n = 39), 17 (43.6%) had PF4-dependent antibodies and 22 (56.4%) had PF4-independent antibodies. CVST occurred almost exclusively in PF4-independent patients (11 of 22 vs 1 of 17; P < .05). Additionally, PF4-independent antibodies bound to 2 distinct epitopes on PF4, the heparin-binding region and a site typical for heparin-induced thrombocytopenia antibodies, whereas PF4-dependent antibodies bound to only the heparin-binding region. CONCLUSION: These findings suggest that VITT antibodies that cause PF4-independent platelet activation represent a unique subset of patients more likely to be associated with CVST, possibly due to the 2 different types of anti-PF4 antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaVaccinesSinus Thrombosis, IntracranialHumansPlatelet Factor 4COVID-19 VaccinesRetrospective StudiesSARS-CoV-2Immunologic FactorsAntibodiesHeparin

Stichwörter der Autor:innen

CVSTPF4SARS-CoV-2VITTadenoviral vector vaccines

Substanzen

Platelet Factor 4COVID-19 VaccinesImmunologic FactorsAntibodiesVaccinesHeparin

Autor:innen und Institutionen

  • Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
  • Michael G DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Departm…

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Public Health Agency of Canada

Zitieren

APA

Huynh, A., Arnold, D. M., Ivetic, N., Clare, R., Hadzi-Tosev, M., Liu, Y., Smith, J. W., Bissola, A. L., Daka, M., Kelton, J. G., & Nazy, I. (2023). Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.06.026

Vancouver

Huynh A, Arnold DM, Ivetic N, Clare R, Hadzi-Tosev M, Liu Y, et al. Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.06.026

BibTeX
@article{Huynh2023,
  author = {Huynh, Angela and Arnold, Donald M and Ivetic, Nikola and Clare, Rumi and Hadzi-Tosev, Milena and Liu, Yang and Smith, James W and Bissola, Anna-Lise and Daka, Mercy and Kelton, John G and Nazy, Ishac},
  title = {Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.06.026}
}
Kostenlos starten →